IDH1 and biliary tract neoplasm: For biliary tract cancer patients with IDH1 mutations, a double-blind phase 3 controlled trial, ClarIDHy, was conducted to evaluate the efficacy of ivosidenib [89]; it was observed that the progression-free survival of the group treated with ivosidenib was significantly prolonged compared to the placebo group (2.7 vs. 1.4 months).